Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines

PHASE3RecruitingINTERVENTIONAL
Enrollment

669

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

August 31, 2026

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

Rcombinant botulinum toxin type A for injection(Eveotox)

Rcombinant botulinum toxin type A for injection(Eveotox)

BIOLOGICAL

OnabotulinumtoxinA (Botox)

OnabotulinumtoxinA (Botox)

BIOLOGICAL

Placebo

Placebo

Trial Locations (15)

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

Peking University First Hospital, Beijing

RECRUITING

Peking University Third Hospital, Beijing

RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

RECRUITING

The First Affiliated Hospital of Jinan University, Guangzhou

RECRUITING

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

RECRUITING

The First Hospital of Hebei Medical University, Shijiazhuang

RECRUITING

The Third Xiangya Hospital of Central South University, Changsha

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

RECRUITING

Huashan Hospital, Fudan University, Shanghai

RECRUITING

Xianyang Hospital of Yan'an University, Xianyang

RECRUITING

West China Hospital, Sichuan University, Chengdu

RECRUITING

Tianjin Medical University General Hospital, Tianjin

RECRUITING

Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

JHM BioPharma (Tonghua) Co. , Ltd.

NETWORK